EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Full-spectrum efficacy of cariprazine across manic and depressive symptoms of bipolar I disorder in patients experiencing mood episodes: Post hoc analysis of pooled randomized controlled trial data

Eduard Vieta, Roger S McIntyre, Jun Yu, Lauren C Aronin, Ken Kramer, Huy-Binh Nguyen

Journal of Affective Disorders · 2024

DOI: 10.1016/j.jad.2024.08.119 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Affective Disorders, 2024. Verfasst von Eduard Vieta und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Psychology, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain. Hauptthemen laut MEDLINE: Bipolar Disorder, Mania, Piperazines. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AbbVie Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Patients with bipolar I disorder may experience mood destabilization or treatment-emergent affective switch (TEAS) from one symptom pole to the other spontaneously or following treatment. Optimal treatment should address symptoms from both poles without precipitating destabilization. METHODS: These were pooled post hoc analyses of data from randomized, double-blind, placebo-controlled studies of cariprazine 3-12 mg/d for bipolar I mania (NCT00488618, NCT01058096, NCT01058668) and cariprazine 1.5 mg/d or 3 mg/d for bipolar I depression (NCT01396447, NCT02670538, NCT02670551). Changes from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) total score at week 6 and Young Mania Rating Scale (YMRS) total score at week 3 were analyzed in each indication using a mixed-effects model for repeated measures. Percentages of patients with increasing levels of endpoint response and TEAS (bipolar mania = MADRS total score ≥ 19; bipolar depression = YMRS score ≥ 16) were determined. RESULTS: Cariprazine significantly reduced manic and depressive symptoms in patients with bipolar I disorder mood episodes. In patients with a manic episode and up to mild baseline depressive symptoms, cariprazine also significantly reduced depressive symptoms. In patients with a depressive episode and manic symptoms in remission at baseline, numerical reduction (without statistical significance) in YMRS indicated no worsening of mania. In both indications, cariprazine-treated patients had numerically greater response rates (presenting symptom pole) than placebo-treated patients; lower percentages of cariprazine- than placebo-treated patients had TEAS at visits where data were collected. LIMITATIONS: Post hoc analysis. CONCLUSION: Results suggested that cariprazine had full-spectrum efficacy across symptoms from both poles in patients with bipolar I disorder mood episodes; TEAS risk was low. Patient-level response suggested that improvement was clinically relevant.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bipolar DisorderManiaPiperazinesHumansMaleFemaleAdultDouble-Blind MethodMiddle AgedTreatment OutcomeDepressionPsychiatric Status Rating ScalesAntipsychotic Agents

Stichwörter der Autor:innen

Bipolar I depressionBipolar I disorderBipolar I maniaCariprazinePatient-level responseTreatment-emergent switch

Substanzen

cariprazinePiperazinesAntipsychotic Agents

Autor:innen und Institutionen

  • Department of Psychiatry and Psychology, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain.
  • Department of Psychiatry and Pharmacology, University of Toronto, Toronto, ON, Canada.
  • Data and Statistical Sciences, AbbVie, Florham Park, NJ, United States.
  • US Medical Affairs, AbbVie, Florham Park, NJ, United States.
  • US Medical Affairs, AbbVie, Florham Park, NJ, United States. Electronic address: binh.nguyen@abbvie.com.

Förderung

  • AbbVie Inc

Zitieren

APA

Vieta, E., McIntyre, R. S., Yu, J., Aronin, L. C., Kramer, K., & Nguyen, H. B. (2024). Full-spectrum efficacy of cariprazine across manic and depressive symptoms of bipolar I disorder in patients experiencing mood episodes: Post hoc analysis of pooled randomized controlled trial data. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2024.08.119

Vancouver

Vieta E, McIntyre RS, Yu J, Aronin LC, Kramer K, Nguyen HB. Full-spectrum efficacy of cariprazine across manic and depressive symptoms of bipolar I disorder in patients experiencing mood episodes: Post hoc analysis of pooled randomized controlled trial data. Journal of Affective Disorders. 2024. doi:10.1016/j.jad.2024.08.119

BibTeX
@article{Vieta2024,
  author = {Vieta, Eduard and McIntyre, Roger S and Yu, Jun and Aronin, Lauren C and Kramer, Ken and Nguyen, Huy-Binh},
  title = {Full-spectrum efficacy of cariprazine across manic and depressive symptoms of bipolar I disorder in patients experiencing mood episodes: Post hoc analysis of pooled randomized controlled trial data},
  journal = {Journal of Affective Disorders},
  year = {2024},
  doi = {10.1016/j.jad.2024.08.119}
}
Kostenlos starten →